{"title":"阿斯利康收购Omthera制药，加强晚期心血管疾病产品线","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I6.1952","DOIUrl":null,"url":null,"abstract":"In its second cardiovascular disease-focused purchase of 2013, AstraZeneca has agreed to acquire Omthera Pharmaceuticals for approximately US$323 M plus Contingent Value Rights that equate to approximately US$120 M in total. With the acquisition, AstraZeneca will gain Omthera’s sole product candidate Epanova™, an omega-3 free fatty acid composition that has successfully completed two Phase III trials in patients with hypertriglyceridaemia and which will face competition in the prescription omega-3 market from GlaxoSmithKline’s Lovaza® (omega-3-acid ethyl esters) and Amarin’s Vascepa® (icosapent ethyl).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"13 44 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AstraZeneca Bolsters Late-Stage Cardiovascular Disease Pipeline with Omthera Pharmaceuticals Purchase\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I6.1952\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In its second cardiovascular disease-focused purchase of 2013, AstraZeneca has agreed to acquire Omthera Pharmaceuticals for approximately US$323 M plus Contingent Value Rights that equate to approximately US$120 M in total. With the acquisition, AstraZeneca will gain Omthera’s sole product candidate Epanova™, an omega-3 free fatty acid composition that has successfully completed two Phase III trials in patients with hypertriglyceridaemia and which will face competition in the prescription omega-3 market from GlaxoSmithKline’s Lovaza® (omega-3-acid ethyl esters) and Amarin’s Vascepa® (icosapent ethyl).\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"13 44 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I6.1952\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I6.1952","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AstraZeneca Bolsters Late-Stage Cardiovascular Disease Pipeline with Omthera Pharmaceuticals Purchase
In its second cardiovascular disease-focused purchase of 2013, AstraZeneca has agreed to acquire Omthera Pharmaceuticals for approximately US$323 M plus Contingent Value Rights that equate to approximately US$120 M in total. With the acquisition, AstraZeneca will gain Omthera’s sole product candidate Epanova™, an omega-3 free fatty acid composition that has successfully completed two Phase III trials in patients with hypertriglyceridaemia and which will face competition in the prescription omega-3 market from GlaxoSmithKline’s Lovaza® (omega-3-acid ethyl esters) and Amarin’s Vascepa® (icosapent ethyl).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
